A balanced care-home guide to antipsychotic consideration, risk, review and avoiding medication-only plans in dementia.
This article provides general education for care providers. It does not replace assessment by the resident’s GP, community services, safeguarding team, mental capacity decision-maker, prescriber or emergency services where required. Resident-identifiable information should not be shared through website enquiries.
Antipsychotics are not a shortcut
Antipsychotics can sometimes have a role in dementia care, but they are not a substitute for assessment, formulation, staff consistency or environmental change. The decision should be careful, documented, proportionate and reviewed.
When discussion may arise
- Severe distress that has not responded to appropriate assessment and support
- Risk of harm to the person or others
- Psychotic symptoms causing significant distress or risk
- Repeated aggression where triggers, pain, delirium and care approach have been considered
- Short-term stabilisation while a fuller care plan is implemented
What should usually happen first
- Review pain, delirium, infection, constipation, hydration, sleep and medication changes
- Review environment, communication and care routines
- Assess triggers, patterns and unmet needs
- Consider capacity, consent and best interests where relevant
- Discuss potential benefits and harms with the person and/or those involved in their care as appropriate
UK prescribing context
Care homes should not be making prescribing decisions, but they play an important role in providing accurate records, monitoring response and escalating concerns. Current CQC guidance notes that risperidone and haloperidol are licensed in the UK for behavioural and psychological symptoms in dementia for up to six weeks, with risperidone generally preferred because of haloperidol’s adverse effect profile.
Extra caution is needed in dementia with Lewy bodies and Parkinson’s disease dementia because of sensitivity to antipsychotic medicines. Prescribers should make those decisions within their own clinical governance arrangements.
Medication must not become the care plan
If medication is used, the team still needs a behavioural plan. Staff should know the target symptom, what to try before medication, what to monitor, what side effects to report, and when review is expected.
Mini case example
A resident had repeated episodes of aggression during evening care. Medication was discussed because staff were frightened. Review showed the behaviour was worst during rushed care after tea, when pain was likely and the resident was fatigued. The care plan was strengthened, pain was escalated for review, and staff recorded clear target behaviours so any medication discussion was based on evidence rather than general concern.
Sources and UK guidance basis
- NICE NG97, recommendations on antipsychotic medicines for agitation, aggression and distress in dementia.
- NICE NG97 patient decision aid on antipsychotic medicines for people living with dementia.
- CQC guidance on appropriate use of psychotropic medicines in adult social care.
What this article cannot do
General articles can help teams think more clearly, but repeated incidents, safeguarding concerns, placement instability, complex family dynamics, prescribing questions or restrictive practice need case-specific review by the appropriate accountable professionals.
First Response Dementia Services provides focused dementia behaviour review, formulation and practical care planning support for care providers. The aim is to help teams understand the pattern, strengthen documentation and agree realistic next steps.